News Release

08/25/2022
Information
FY2022 Q2 Analyst Call Q&A Summary
06/11/2022
Information
Chief Scientific Officer of Cullgen Inc. will be speaking at the 30th Annual Meeting of the Japanese Breast Cancer Society
06/11/2022
Information
Beijing Continent enrolls the first subject of pirfenidone capsules Phase III clinical trial for pneumoconiosis
05/24/2022
Information
FY2022 Q1 Analyst Call Q&A Summary
04/15/2022
Information
GNI Group FY2021 Annual General Meeting Q&A Summary
01/31/2022
Information
Frequently Asked Questions Updated File (2022-JAN-31)
01/31/2022
Information
Frequently Asked Questions Updated (2022-JAN-31)
01/04/2022
Information
2022 New Year Greeting
12/29/2021
Information
GNI Group's New Qualification as a Margin Trading Stock
12/28/2021
Information
GNI Group Ltd. Ranks 32nd in 2021 Japan Technology Fast 50
10/26/2021
Information
Berkeley Advanced Biomaterials LLC Exhibited in the U.S. and China Orthopedics Conferences
06/22/2021
Information
Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer
04/16/2021
Information
Ranked in the Financial Times, "High-Growth Companies Asia-Pacific 2021" for the second consecutive year
01/04/2021
Information
New Year Greeting
11/02/2020
Information
Chinese Journal of Tuberculosis and Respiratory Diseases recommended the use of Pirfenidone as an anti-fibrosis therapy for COVID-19 patients in China